NCT03541447View on ClinicalTrials.gov

Tolvaptan-Octreotide LAR Combination in ADPKD

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

December 23, 2021

Study Completion Date

December 23, 2021

Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
DRUG

Tolvaptan

Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.

DRUG

Octreotide LAR

A single dose of two 20 mg i.m. injections.

OTHER

Placebo

A single dose of two 20 mg i.m. injections.

Trial Locations (1)

24020

CRC per le Malattie Rare Aldo e Cele Daccò, Ranica

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Italy S.r.l.

UNKNOWN

lead

Mario Negri Institute for Pharmacological Research

OTHER